Predictors of Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiation Followed by Consolidative Durvalumab

This journal activity provides practitioners with the knowledge for practice improvement in treating patients with non-small cell lung cancer undergoing definitive chemoradiation followed by consolidative durvalumab.

Please visit https://www.advancesradonc.org/article/S2452-1094(22)00236-6/fulltext to read the related journal article online. 

This activity is available from March 14, 2023, through 11:59 p.m. Eastern time on March 13, 2025.

Target Audience

This course is designed to meet the interest of radiation oncologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify potential radiation planning parameters that may better improve the side effect profile in patients with non-small cell lung cancer undergoing definitive chemoradiation followed by consolidative durvalumab.

 

 

 

 

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
03/14/2023
Course expires: 
03/13/2025
Cost:
$49.00
Rating: 
0

Robert C. Miller, MD, MBA, FASTRO is employed by the University of Tennessee and has stock in Tekcapital Plc. and Belluscura Ltd.

The person(s) above served as the developer(s) of this activity. Additionally, Education Committee had control over the content of this activity.

All relevant relationships have been mitigated.

 

Disclosure link: 
Committee Disclosure

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$49.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $49
  • Member: $0


Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

 

 

 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.